AIM:BVXP

Stock Analysis Report

Executive Summary

Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.

Risks

  • Bioventix is covered by less than 3 analysts.

Share Price & News

How has Bioventix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.0%

AIM:BVXP

0.003%

GB Biotechs

0.4%

GB Market


1 Year Return

30.8%

AIM:BVXP

22.6%

GB Biotechs

-6.2%

GB Market

BVXP outperformed the Biotechs industry which returned 22.6% over the past year.

BVXP outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -6.2% over the past year.


Share holder returns

BVXPIndustryMarket
7 Day2.0%0.003%0.4%
30 Day3.6%2.1%-4.7%
90 Day0.9%1.8%-2.3%
1 Year36.2%30.8%23.6%22.6%-1.7%-6.2%
3 Year295.5%249.2%12.0%10.1%16.8%2.9%
5 Year713.3%569.8%54.1%50.4%24.2%-2.3%

Price Volatility Vs. Market

How volatile is Bioventix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bioventix undervalued based on future cash flows and its price relative to the stock market?

35.77x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Bioventix's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Bioventix's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Bioventix is good value based on earnings compared to the GB Biotechs industry average.

Bioventix is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Bioventix is poor value based on expected growth next year.


Price Based on Value of Assets

Bioventix is overvalued based on assets compared to the GB Biotechs industry average.


Next Steps

Future Growth

How is Bioventix expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

10.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Bioventix's revenue is expected to grow by 8.8% yearly, however this is not considered high growth (20% yearly).

Bioventix's earnings are expected to grow by 10.7% yearly, however this is not considered high growth (20% yearly).

Bioventix's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Bioventix's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.

Bioventix's earnings growth is expected to exceed the low risk savings rate of 1.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Bioventix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Bioventix performed over the past 5 years?

26.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bioventix has delivered over 20% year on year earnings growth in the past 5 years.

Bioventix's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Bioventix's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.


Return on Equity

Bioventix made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

Bioventix used its assets more efficiently than the GB Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Bioventix has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Bioventix's financial position?


Financial Position Analysis

Bioventix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Bioventix's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Bioventix has no debt.

Bioventix has not taken on any debt in the past 5 years.

Bioventix has no debt, it does not need to be covered by operating cash flow.

Bioventix has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Bioventix has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Bioventix's current dividend yield, its reliability and sustainability?

2.24%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Bioventix's pays a higher dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.05%).

Bioventix's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.65%).

Whilst dividend payments have been stable, Bioventix has been paying a dividend for less than 10 years.

Dividend payments have increased, but Bioventix only paid a dividend in the past 9 years.


Current Payout to Shareholders

Dividends paid are covered by earnings (1.6x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Bioventix's salary, the management and board of directors tenure and is there insider trading?

UK£358k

CEO Compensation


CEO

Peter Harrison (61yo)

0.0yrs

Tenure

UK£358,242

Compensation

Mr. Peter J. Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development and ...


CEO Compensation Analysis

Peter's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Insufficient data for Peter to compare compensation growth.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Peter Harrison (61yo)

    CEO & Director

    • Tenure: 0.0yrs
    • Compensation: UK£358.24k
  • Treena Turner

    Finance Director & Director

    • Tenure: 0.0yrs
    • Compensation: UK£4.28k

Board Members

  • Ian Nicholson (59yo)

    Non-Executive Chairman

    • Tenure: 14.8yrs
    • Compensation: UK£26.13k
  • Nick McCooke (66yo)

    Non-Executive Director

    • Tenure: 5.6yrs
    • Compensation: UK£23.61k
  • Peter Harrison (61yo)

    CEO & Director

    • Tenure: 0.0yrs
    • Compensation: UK£358.24k
  • Treena Turner

    Finance Director & Director

    • Tenure: 0.0yrs
    • Compensation: UK£4.28k

Company Information

Bioventix PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioventix PLC
  • Ticker: BVXP
  • Exchange: AIM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£199.793m
  • Shares outstanding: 5.14m
  • Website: https://www.bioventix.com

Number of Employees


Location

  • Bioventix PLC
  • 27-28 Eastcastle Street
  • London
  • Greater London
  • W1W 8DH
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BVXPAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPApr 2010
51BDB (Deutsche Boerse AG)YesOrdinary SharesDEEURApr 2010

Biography

Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide. The company offers a portfolio of purified SMAs for thyro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 21:51
End of Day Share Price2019/08/23 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.